---
figid: PMC4728196__gr1
figtitle: PI3K pathway with respective PI3K inhibitors
organisms:
- NA
pmcid: PMC4728196
filename: gr1.jpg
figlink: /pmc/articles/PMC4728196/figure/fig0005/
number: F1
caption: The PI3K pathway with respective PI3K inhibitors. When PI3K is activated,
  phosphatidylinositol 3,4,5-trisphosphate (PIP3) is generated from phosphatidylinositol
  3,4-bisphosphate (PIP2), and recruits AKT to the cell membrane [, ]. This leads
  to a conformational change and phosphorylation of AKT and its subsequent activation.
  AKT then translocates to the cytoplasm and nucleus, where phosphorylation of various
  downstream substrates involved in the regulation of multiple cellular functions,
  including proliferation, survival and growth occurs. The PI3K pathway is one of
  the most frequently activated signalling pathways in human cancers, affecting 30–50%
  of tumours, making it a rational target for novel anticancer drug development. The
  red arrows indicate the respective mechanisms of action of different PI3K inhibitors,
  which include the dual PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors and isoform-selective
  PI3K inhibitors. Individual examples of different PI3K inhibitors in clinical testing
  are shown in the figure. The table in the figure lists the regulatory and catalytic
  subunits of the respective PI3K classes.
papertitle: 'Drugging PI3K in cancer: refining targets and therapeutic strategies.'
reftext: Timothy A Yap, et al. Curr Opin Pharmacol. 2015 Aug;23:98-107.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8804961
figid_alias: PMC4728196__F1
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC4728196__F1
ndex: d0ddff36-df0d-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4728196__gr1.html
  '@type': Dataset
  description: The PI3K pathway with respective PI3K inhibitors. When PI3K is activated,
    phosphatidylinositol 3,4,5-trisphosphate (PIP3) is generated from phosphatidylinositol
    3,4-bisphosphate (PIP2), and recruits AKT to the cell membrane [, ]. This leads
    to a conformational change and phosphorylation of AKT and its subsequent activation.
    AKT then translocates to the cytoplasm and nucleus, where phosphorylation of various
    downstream substrates involved in the regulation of multiple cellular functions,
    including proliferation, survival and growth occurs. The PI3K pathway is one of
    the most frequently activated signalling pathways in human cancers, affecting
    30–50% of tumours, making it a rational target for novel anticancer drug development.
    The red arrows indicate the respective mechanisms of action of different PI3K
    inhibitors, which include the dual PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors
    and isoform-selective PI3K inhibitors. Individual examples of different PI3K inhibitors
    in clinical testing are shown in the figure. The table in the figure lists the
    regulatory and catalytic subunits of the respective PI3K classes.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Tie
  - Ras85D
  - InR
  - as
  - hop
  - bsk
  - Pten
  - Pdk1
  - Crtc
  - ras
  - Ras64B
  - Mtor
  - Tor
  - Raf
  - Akt
  - cass
  - Dsor1
  - Mtk
  - Dif
  - dl
  - Rel
  - gig
  - Debcl
  - Stat92E
  - Erk7
  - rl
  - foxo
  - Dt
  - p53
  - betaTub60D
  - hth
  - tor
  - Egfr
  - CycE
  - cyc
  - raptor
  - WDR79
  - tral
  - rump
  - MED17
  - SF1
  - Irbp
  - Thor
  - eIF4E1
  - ab
  - Appl
  - Rpn5
  - Caf1-55
  - cav
  - Hrb27C
  - Rpt5
  - DCTN2-p50
  - l(1)G0020
  - Taf4
  - Rpn2
  - Sap-r
  - scb
  - Gp150
  - DCTN1-p150
  - Vps15
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - PTEN
  - PDK1
  - PDPK1
  - CRTC2
  - KRAS
  - HRAS
  - NRAS
  - MTOR
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - BAD
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - TSC2
  - BCL2
  - BCL2L1
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - EPHB2
  - MAPK1
  - MAPK3
  - FOXO1
  - TCF12
  - MDM2
  - TP53
  - TP63
  - TP73
  - RORC
  - CRTC1
  - ANXA6
  - UBASH3B
  - EPHA4
  - EIF4EBP1
  - EIF4E
  - APP
  - SUCLA2
  - ERG
  - FOS
  - IL2RA
  - PSMD12
  - FSCN1
  - TNFRSF1A
  - PMPCA
  - H3P44
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - NBPF10
  - CUX1
  - SART3
  - THOC1
  - PPP1R12C
  - SIRPA
  - ITGA1
  - ITGA10
  - ITGA11
  - ITGA2
  - ITGA2B
  - ITGA3
  - ITGA4
  - ITGA5
  - ITGA6
  - ITGA7
  - ITGA8
  - ITGA9
  - ITGAD
  - ITGAE
  - ITGAL
  - ITGAM
  - ITGAV
  - ITGAX
  - ITGB1
  - ITGB2
  - ITGB3
  - ITGB4
  - ITGB5
  - ITGB6
  - ITGB7
  - ITGB8
  - ITGBL1
  - ABL1
  - ANPEP
  - CTR9
  - CHAF1A
  - RAB3GAP2
  - PIK3C3
  - AZD8186
  - BEZ235
  - GSK2126458
  - GDC-0980
  - PF-04691502
  - tyrosine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
